PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.

Mette J Nielsen,Grace E Dolman,Rebecca Harris,Peder Frederiksen,Jane Chalmers,Jane I Grove,William L Irving,Morten A Karsdal,Keyur Patel,Diana Julie Leeming,Indra Neil Guha

JHEP reports : innovation in hepatology（2023）

引用 0|浏览3

暂无评分

摘要

We tested novel proteins of liver scarring (PRO-C3) in two groups of liver patients with advanced disease to see if they could predict clinical events. We found that this marker and an established test called ALBI were both independently associated with future liver-related clinical outcomes.

查看译文

关键词

advanced liver disease,clinical outcomes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要